Article 54 of Regulation (EU) 2017/745 requires the Notified Body to follow the clinical evaluation consultation procedure, known as the CECP, before issuing a certificate for certain implantable Class III devices and certain Class IIb active devices intended to administer or remove a medicinal product. Under the CECP, the Notified Body sends its clinical evaluation assessment report together with the manufacturer's clinical evaluation documentation to the Commission, which forwards the file to an independent expert panel for a scientific opinion. The procedure is carried out in accordance with Annex IX Section 5.1 of the Regulation. The expert panel's opinion is an input to the Notified Body's decision, not a veto, but the Notified Body must give due consideration to the opinion and document how the views were taken into account in the final certificate decision. The CECP adds calendar time that neither the manufacturer nor the Notified Body controls.

By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.

TL;DR

  • Article 54 of Regulation (EU) 2017/745 establishes the clinical evaluation consultation procedure (CECP) for certain Class III implantable devices and certain Class IIb active devices intended to administer or remove a medicinal product.
  • The procedural steps the Notified Body must follow are set out in Annex IX Section 5.1 of the Regulation.
  • Under the CECP, the Notified Body sends the clinical evaluation assessment report and the manufacturer's clinical evaluation documentation via the Commission to an independent expert panel for a scientific opinion.
  • Article 54 lists narrow exceptions, including modifications of devices already certified for the same manufacturer and certain well-established technologies.
  • The expert panel's opinion is not binding on the Notified Body, but the Notified Body must give due consideration to the opinion and document how it was taken into account.
  • Article 54 is distinct from the Article 55 scrutiny mechanism. The two procedures can interact but must not be confused.
  • The CECP adds weeks to months of calendar time to the Class III certification path and must be budgeted from day one on any affected project.

Why Article 54 exists

The Article 54 consultation procedure exists because the consequences of a wrong certification decision on a novel implantable Class III device are measured in patient harm, not paperwork. The Regulation takes the view that the most consequential Class III clinical evaluation decisions should not rest inside a single Notified Body review team. An independent panel of clinical and technical experts, convened by the Commission, reads the same clinical evaluation assessment report and renders a scientific opinion. The Notified Body remains the decision-maker, but the decision is made with a second set of eyes on the file.

For a startup running a Class III implantable project, Article 54 is not an abstract governance mechanism. It is a procedural gate that adds calendar time, shapes the Notified Body's behaviour during review, and determines whether the clinical evaluation is ready to leave the building in the first place. A founder who reaches the CECP stage with a weak clinical evaluation report discovers the weakness in writing, from experts who do not know the device, in an opinion that becomes part of the file. That is not a place to be surprised.

This post is the deep dive on the Article 54 CECP. The conformity assessment procedure that contains it is walked step by step in the Class III conformity assessment procedure. The conceptual framing of what Class III means is in Class III Medical Devices Under MDR: The Highest Risk Category Demystified.

What Article 54 requires

Article 54 of Regulation (EU) 2017/745 requires Notified Bodies to follow the clinical evaluation consultation procedure for specific device categories before issuing a certificate. The procedural mechanics. What the Notified Body sends, where it sends it, how the expert panel is engaged, how the opinion is returned, and how the Notified Body must handle the opinion in its final decision. Are set out in Annex IX Section 5.1 of the Regulation.

The triggering categories are narrowly defined. Article 54 applies to implantable Class III devices, with listed exceptions, and to Class IIb active devices intended to administer and/or remove a medicinal product covered by point 5.3 of Annex VIII Rule 12 (in substance. The founder must read the actual text for the exact formulation). For devices outside these categories, Article 54 does not apply and no consultation is required. For devices inside these categories, the consultation is mandatory unless one of the exceptions in Article 54 itself is met.

The text that matters is in Article 54 paragraphs 1 and 2 and in Annex IX Section 5.1. The exact list of exceptions, the exact interaction with Article 61 clinical evaluation requirements, and the exact points at which the clock runs are in the consolidated text and must be read there before a project plan is built on top.

The triggering conditions

Three conditions together determine whether the CECP applies to a specific device.

Device category. The device must fall within the scope of Article 54. Implantable Class III (with the exceptions listed in Article 54 itself) or the specific category of Class IIb active devices intended to administer or remove a medicinal product that the Article captures. A Class III non-implantable device is outside Article 54. A Class IIb active device that does not administer or remove a medicinal product is outside Article 54. A Class I, IIa, or (non-qualifying) IIb device is outside Article 54.

Procedural stage. The consultation applies during conformity assessment, before the Notified Body issues the EU technical documentation assessment certificate. The Notified Body triggers the procedure after it has prepared its clinical evaluation assessment report and before it concludes its decision on the certificate.

No applicable exception. Article 54 itself lists exceptions where the consultation does not apply. Including, in substance, modifications of a device already certified for the same manufacturer, devices certified under procedures where a previous CECP opinion on an equivalent device is available, and certain well-established technologies. The exact list, with the exact language, is in Article 54 of the Regulation and must be checked against the current consolidated text for each specific device. The wording has been refined in practice and only the actual text gives a reliable answer.

If all three conditions are satisfied, the CECP runs. If any one of them is not, it does not.

The expert panel process

The CECP is operated through the Commission's expert panels on medical devices. Expert panels are groups of independent clinical, scientific, and technical experts designated to provide scientific and technical advice in support of the consistent application of the Regulation. They are convened around specific medical specialities. Cardiovascular, orthopaedic, neurological, and so on. So that the panel that reviews a file has subject-matter competence in the device's clinical area.

When a Notified Body triggers an Article 54 consultation, the flow in substance is: the Notified Body prepares its clinical evaluation assessment report (CEAR) based on its review of the manufacturer's clinical evaluation, assembles the supporting documentation, and sends the package to the Commission. The Commission forwards the file to the relevant expert panel. The panel reviews the documentation and determines whether it will provide a scientific opinion. Where the panel decides to issue an opinion, it issues one within the timeframe set out in the applicable procedural rules. The opinion is returned to the Notified Body via the Commission.

The expert panel is not a second Notified Body. It does not audit the QMS, it does not re-assess the technical file end to end, and it does not issue the certificate. Its output is a scientific opinion on the clinical evaluation. Specifically, a views document on whether the clinical evidence and the Notified Body's assessment of that evidence support the conclusions the Notified Body is about to rely on.

The clinical evaluation consultation procedure (CECP)

The CECP is the name commonly used, inside Notified Bodies and in practitioner documentation, for the procedure that Article 54 and Annex IX Section 5.1 operate. The acronym does not appear in the Regulation itself, but the procedure it describes is the one set out there.

The CECP package, at a working level, contains the manufacturer's clinical evaluation report, the underlying clinical data, the risk management file summary as it bears on clinical benefit-risk, the Notified Body's clinical evaluation assessment report, and any supporting documentation the expert panel needs to form a view. The panel reads the CEAR and the underlying evidence and asks the question the CEAR already tried to answer: does the clinical evidence, taken as a whole, support the benefit-risk determination and the intended purpose of the device?

Where the panel's view aligns with the Notified Body's CEAR, the opinion confirms the direction of travel and the Notified Body proceeds to its decision. Where the panel diverges, the opinion flags the divergence and the Notified Body must document how it considered the panel's views before deciding. The Notified Body is not required to follow the opinion, but it is required to explain its reasoning if it does not.

The consultation timeline

The CECP adds calendar time to a project that already runs long. The honest order of magnitude for the consultation step itself is several weeks to several months from the moment the Notified Body sends the file to the Commission to the moment the opinion is back in the Notified Body's hands and incorporated into the final decision. The exact duration depends on the panel's cadence, the complexity of the device, the quality of the CEAR, and whether the panel has questions that bounce back to the Notified Body for clarification.

For the founder, two implications follow. First, the CECP time is not inside the Notified Body's control. The Notified Body cannot expedite an expert panel opinion, and promising a customer that the Class III certificate will land on a fixed date that does not accommodate the CECP is the kind of promise that ends a career. Second, the time the CECP adds is on top of the ordinary Annex IX per-device review, not inside it, so the project plan has to account for it explicitly as a distinct block on the critical path.

A Class III implantable project that budgets Article 54 time from day one runs smoother than one that discovers the requirement mid-review. The dominant failure mode is projects built on Class IIb timelines with a generic markup. The markup is almost never large enough.

What the opinion covers

The expert panel's scientific opinion covers the clinical evaluation. What the evidence says, how the Notified Body assessed it, and whether the conclusions on benefit-risk and intended purpose are supported. The opinion typically addresses the strength of the clinical data, the appropriateness of the clinical investigation design where one was performed, the acceptability of any equivalence reasoning under Article 61, the benefit-risk analysis against the risk management file, the post-market clinical follow-up plan, and the adequacy of the intended purpose and indications in light of the evidence.

The opinion does not cover the QMS audit, the manufacturing controls, the electrical safety testing, the biocompatibility evaluation beyond its clinical relevance, or the labelling compliance with Annex I Chapter III. Those parts of the conformity assessment remain with the Notified Body, and the panel's opinion does not reach them.

The Notified Body must give due consideration to the opinion and document how the opinion was taken into account in the final certificate decision. The documentation trail from the opinion to the decision is itself part of the file. If a competent authority, under Article 55 or otherwise, later reviews the certification, the Notified Body's handling of the Article 54 opinion is visible and auditable.

Common mistakes

  • Assuming Article 54 is optional or negotiable. It is not. Where the device falls within scope and no exception applies, the consultation is mandatory and the Notified Body cannot route around it.
  • Confusing Article 54 with Article 55. Article 54 is the clinical evaluation consultation procedure with an expert panel. Article 55 is the scrutiny mechanism with competent authorities and the publicly available summary of safety and clinical performance. They are distinct procedures that can apply to the same device and must not be collapsed into one concept. For the Article 55 detail, see the Article 55 scrutiny procedure.
  • Building the project plan on a clinical evaluation that was never going to survive the CECP. If the CEAR would not pass a close expert reading, sending it to an expert panel will not make it pass. It will make the weakness part of the file.
  • Budgeting the CECP as a rounding error. The consultation adds weeks to months. Treating it as a one-week step is how Class III timelines slip by a full quarter in a single review cycle.
  • Missing the Article 54 exceptions. The exceptions for modifications of already-certified devices from the same manufacturer can genuinely apply. But only when the evidence truly supports the exception. Assuming an exception applies without reading the exact Article 54 text and confirming with the Notified Body is the fastest way to discover it does not.
  • Treating the expert panel as an adversary. The panel is an independent scientific body. The project's interest is in sending a file that answers the question the panel will ask, not in anticipating which arguments might win a debate.

The Subtract to Ship angle

Article 54 cannot be subtracted. Where it applies, it applies. What Subtract to Ship can do is make the CECP survivable by ensuring that the clinical evaluation report, the Notified Body's CEAR, and the supporting file are readable, tightly argued, and traceable to specific MDR provisions. So that the expert panel's reading is as short as a high-quality reading can be.

Cut every speculative analysis from the clinical evaluation. Cut every piece of evidence that does not bear on a specific Annex I GSPR or a specific benefit-risk question. Cut every sentence that argues the device is safe by restating the intended purpose. What remains is the actual clinical argument. The one the panel will read. The discipline that produces a small book-quality CEAR is the same discipline that produces a CEAR that clears an expert panel review on the first pass. For the full methodology, see the Subtract to Ship framework for MDR compliance.

Reality Check. Where do you stand on Article 54?

  1. Have you confirmed whether your device falls within the scope of Article 54. Implantable Class III or a Class IIb active device intended to administer or remove a medicinal product. By reading the actual text of Article 54?
  2. If your device is in scope, have you checked the Article 54 exceptions against your device and documented whether any exception applies?
  3. Does your project plan include Article 54 consultation time as a distinct block on the critical path, sized in weeks to months rather than days?
  4. Is your clinical evaluation report built to withstand a close reading by an independent expert panel that does not know your device?
  5. Has your Notified Body confirmed whether Article 54 will apply to your file and what their internal CEAR preparation step looks like?
  6. Do you understand the distinction between Article 54 (clinical evaluation consultation with an expert panel) and Article 55 (scrutiny mechanism with competent authorities and public summary)?
  7. Is your clinical evaluation traceable to Article 61, Annex XIV, and specific GSPRs. Or is it a narrative document that would struggle under a line-by-line expert reading?

Frequently Asked Questions

When does MDR Article 54 consultation apply? Article 54 of Regulation (EU) 2017/745 applies to implantable Class III devices. With the narrow exceptions listed in Article 54 itself. And to Class IIb active devices intended to administer or remove a medicinal product where the Article captures them. Where the device is in scope and no exception applies, the Notified Body must follow the clinical evaluation consultation procedure before issuing a certificate.

What is the CECP? CECP stands for clinical evaluation consultation procedure. It is the working name for the procedure established by Article 54 and carried out under Annex IX Section 5.1 of the Regulation. Under the CECP, the Notified Body sends the clinical evaluation assessment report and supporting documentation via the Commission to an independent expert panel, which issues a scientific opinion that the Notified Body must give due consideration to in its final certificate decision.

Is the expert panel opinion binding on the Notified Body? No. The Article 54 expert panel opinion is an input to the Notified Body's decision, not a veto. The Notified Body remains the decision-maker on certificate issuance. However, the Notified Body must give due consideration to the opinion and document how the panel's views were taken into account in the final decision. The handling of the opinion is itself part of the file and is visible to competent authorities under the Article 55 scrutiny mechanism.

How much time does Article 54 add to a Class III certification? The honest order of magnitude is several weeks to several months of calendar time added on top of the ordinary Annex IX per-device review. The exact duration depends on the expert panel's cadence, the complexity of the device, the quality of the Notified Body's clinical evaluation assessment report, and whether the panel has questions that require clarification rounds.

Are Article 54 and Article 55 the same procedure? No. Article 54 establishes the clinical evaluation consultation procedure with independent expert panels. Article 55 establishes a distinct scrutiny mechanism, which involves notification to competent authorities and publication of summaries of safety and clinical performance via Eudamed. The two procedures can apply to the same device and interact in practice, but they are established by separate articles and have separate functions.

Where in the MDR is the Article 54 procedure actually described? The substance of the obligation is in Article 54 of Regulation (EU) 2017/745. The procedural steps the Notified Body must follow. What to send, when to send it, and how the opinion is handled. Are set out in Annex IX Section 5.1 of the Regulation. Both texts must be read together for a complete picture of the CECP.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Article 54 (clinical evaluation consultation procedure for certain Class III and Class IIb devices), Article 55 (mechanism for scrutiny of conformity assessments of certain Class III and Class IIb devices), Annex IX Section 5.1 (procedure for the assessment of the clinical evaluation). Official Journal L 117, 5.5.2017.

This post is part of the Device Classification & Conformity Assessment series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. Article 54 is where a Class III implantable project's clinical evaluation leaves the bilateral conversation between manufacturer and Notified Body and enters the expert panel's reading room. The discipline that built a tight clinical file is the same discipline that clears the CECP on the first pass.